Compare Globus Medical Inc. Class A Common Stock (GMED) vs VanEck Uranium & Nuclear ETF (NLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs VanEck Uranium & Nuclear ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while VanEck Uranium & Nuclear ETF trades at $92.57 (market cap $3.37B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3× VanEck Uranium & Nuclear ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and VanEck Uranium & Nuclear ETF for 9 Days on average.
| GMED | NLR | |
|---|---|---|
Market Cap | $10.25B | $3.37B |
Volume | 1,108,124 | 376,734 |
Sector | Health | Sector/Thematic |
52-Week High | $96.82 | $164.37 |
52-Week Low | $58.33 | $94.52 |
Typical Hold Time | 0 Days | 9 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NLR, the VanEck Uranium and Nuclear ETF, trades at $99.38, down 0.82% on the day amid a bearish technical signal. The ETF is positioned to benefit from growing demand for nuclear power driven by AI data centers and government support, as highlighted by recent news of a major Google-Constellation deal and U.S. funding for new reactors. However, key financial ratios are unavailable, and technical indicators show selling pressure with moving averages and oscillators in bearish alignment.
The outlook for NLR is mixed, with long-term catalysts from nuclear energy adoption offset by near-term volatility and lack of transparent fundamentals. Risks include sector-specific headwinds and expense ratio comparisons, but institutional interest from firms like Bank of America suggests confidence. Investors should weigh the ETF's thematic exposure against its technical weakness and opaque financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →
